Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenetic Biosciences (XBIO) EBITDA Margin (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed EBITDA Margin for 6 consecutive years, with 53.04% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 2827.0% year-over-year to 53.04%, compared with a TTM value of 115.8% through Sep 2025, up 5702.0%, and an annual FY2024 reading of 168.16%, up 963.0% over the prior year.
  • EBITDA Margin was 53.04% for Q3 2025 at Xenetic Biosciences, up from 122.8% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 53.04% in Q3 2025 and bottomed at 248.31% in Q1 2024.
  • Average EBITDA Margin over 3 years is 157.04%, with a median of 169.41% recorded in 2024.
  • Peak annual rise in EBITDA Margin hit 10630bps in 2024, while the deepest fall reached -9725bps in 2024.
  • Year by year, EBITDA Margin stood at 186.87% in 2023, then grew by 9bps to 169.41% in 2024, then surged by 69bps to 53.04% in 2025.
  • Business Quant data shows EBITDA Margin for XBIO at 53.04% in Q3 2025, 122.8% in Q2 2025, and 158.85% in Q1 2025.